Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares rose about 29% over 21 trading days. Q2 revenue grew 52% year over year, and finalized Medicare coverage across kidney, heart and lung surveillance supports the business outlook.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Quarterly Profit Surge ⢠Strong Liquidity ⢠Historical Losses CDNA's strong latest-quarter profitability, liquidity, and low leverage improve its outlook, but investors should weigh these gains against full-year losses and deeply negative retained earnings.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly advance ⢠Near-term overbought ⢠Key support watch Support Level: $52.30â$52.60 Resistance Level: $54.28 CDNA is in a strong last-month uptrend, but with RSI near 73, watch $54.28 resistance and $52.30â$52.60 support for breakout or pullback confirmation.
Sentiment & News
Key News Insights: ⢠Mixed institutional flows ⢠Defensive stock appeal ⢠Valuation caution CareDx drew mixed signals from new institutional buying, insider-style selling, and defensive-stock attention, suggesting cautious investor interest amid valuation and performance concerns.
AI Summary
CareDx's Medicare-backed AlloSure expansion and NavDx oncology entry elevate it from a transplant turnaround to a higher-margin diagnostics platform, but with shares already pricing in much of the upside, investors should wait for sustained test-volume growth and recurring profitabilityânot one-off GAAP earningsâto validate the re-rating.
Description
CareDx, Inc. develops and commercializes diagnostic tests and software for transplant patients and clinicians, including donor-derived cell-free DNA and gene-expression assays for surveillance of kidney, heart and lung allografts as well as high-resolution HLA typing, chimerism testing and transplant management tools. The company markets its offerings directly and through distributors and maintains licensing arrangements with partners such as Illumina and Cibiltech. Founded in 1998 and headquartered in South San Francisco, CareDx changed its name from XDx in 2014.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 28 | Oct 5 | CDNA | CareDx, Inc | Shares rose about 29% over 21 trading days. Q2 revenue grew 52% year over year, and finalized Medicare coverage across kidney, heart and lung surveillance supports the business outlook. | Closed | +8.1% |
| Aug 27 | Sep 3 | CDNA | CareDx, Inc | CareDx combines strong momentum with concrete operating catalysts: shares gained 38.6% through August 27, Q2 revenue rose 52%, and EPS of $0.37 beat $0.22 consensus. Finalized Medicare coverage and strong cash generation reinforce the near-term case. | Closed | -4.8% |